Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) is a global leader in innovative eye care solutions, specializing in visioncare products and ophthalmic surgical equipment. This page aggregates official company announcements, financial disclosures, and strategic developments for stakeholders tracking its market position.
Access real-time updates on product innovations, regulatory milestones, and financial performance. Investors and industry professionals will find curated press releases covering earnings reports, partnership announcements, and clinical trial outcomes.
Key content includes updates on contact lens technologies, intraocular lens advancements, and surgical system innovations. All materials are sourced directly from Alcon's communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to Alcon's latest developments. Combine this resource with SEC filings and market analysis tools for comprehensive investment research.
Alcon (NYSE: ALC) has successfully completed its acquisition of Ivantis, the developer of the Hydrus Microstent, which is designed for minimally invasive glaucoma surgery (MIGS). The integration of Ivantis associates is aimed at ensuring continuity for customers while expanding the reach of the Hydrus Microstent to more markets. The device has shown significant clinical benefits over five years, including reduced need for medication and surgeries. Alcon's CEO anticipates this acquisition will enhance their surgical portfolio and drive growth in the glaucoma market.
Alcon has launched PRECISION1, the first daily disposable contact lens using SMARTSURFACE Technology, enhancing visual performance and comfort. Available in Europe, North America, and parts of Latin America and Asia, PRECISION1 for Astigmatism addresses the needs of up to 41% of patients with astigmatism, as only 10% currently wear toric lenses. The lenses aim to improve retention rates among new users by tackling common issues like poor vision and comfort. Alcon emphasizes its commitment to eye care and enhancing the lens-wearing experience.
Alcon reported third quarter sales of $2.1 billion, a 15% increase year-over-year, reflecting growth across all Surgical and Vision Care segments. The company achieved a core diluted EPS of $0.54, and a core operating margin of 17.7%. Cash flow from operations reached $958 million, with free cash flow at $578 million. Alcon plans to expand in the surgical glaucoma market through the intended acquisition of Ivantis. Despite a net debt position of $2.5 billion, the company ended the quarter with a cash balance of $1.6 billion.
Alcon (NYSE: ALC) reported a strong performance for Q3 and the first nine months of 2021, with sales reaching $2.1 billion, a 15% increase compared to the same period in 2020. Key segments, Surgical and Vision Care, showed significant growth, benefiting from innovation and market recovery post-pandemic. Cash from operations totaled $958 million, with free cash flow at $578 million. Alcon is expanding its surgical glaucoma offerings through an intended acquisition of Ivantis, highlighting its commitment to innovation.
Alcon has introduced SMART Solutions, a digital platform for ophthalmology, furthering its leadership in integrated surgical technologies. The application SMARTCataract is now being installed with U.S. customers, enhancing clinic-to-OR connectivity with cloud-based planning. With access to data from more than 2 million cases through the ORA SYSTEM, surgical accuracy and efficiency are emphasized. Alcon aims for broader rollout in 2022, showcasing advancements at the American Academy of Ophthalmology meeting.
Alcon (NYSE: ALC) has announced its intention to acquire Ivantis, the maker of the Hydrus Microstent, a minimally invasive glaucoma surgery device. The acquisition, valued at $475 million, aims to strengthen Alcon's surgical glaucoma portfolio. The Hydrus Microstent has shown a strong safety profile in a five-year study, with 65% of patients remaining medication-free. This acquisition seeks to expand access to effective glaucoma treatments worldwide, addressing a significant unmet patient need. The transaction is expected to close in the first quarter of 2022, pending regulatory approval.
Alcon will showcase its innovative TOTAL30 contact lenses at the American Academy of Optometry Annual Meeting in Boston from November 3-6, 2021. The TOTAL30 lens, featuring Water Gradient technology, is designed for comfort, even at day 30 of wear. Alongside the launch, Alcon will present clinical data supporting its product portfolio, including DAILIES TOTAL1 for Astigmatism and updates to its dry eye range. The event will include hands-on experiences, scientific presentations, and new product previews aimed at enhancing patient and professional satisfaction.
Alcon, a leader in eye care, has won the FutureEdge 50 Award for its ForeSight enterprise data and analytics platform, recognizing its innovative approach to technology. This platform, developed in just 67 days, played a crucial role in Alcon's transition to an independent company by separating IT services from its former parent. The award underscores Alcon's commitment to cost and time savings while establishing its leadership in data analytics. This achievement follows multiple accolades for the company in 2021, including the CIO of the Year ORBIE Award.
Alcon reported strong financial results for Q2 2021, with worldwide sales reaching $2.1 billion, a 75% increase year-over-year. Diluted earnings per share were $0.31, with core diluted earnings at $0.56. Surgical net sales surged 100% and Vision Care sales increased 49%. The company raised its full-year sales outlook to $8.0 to $8.2 billion. Operating income for Q2 was $229 million, significantly improved from last year. Alcon's cash position was $1.4 billion, with a net debt of $2.8 billion.
